Allopurinol 300 mg
Allopurinol 300 mg is a pharmaceutical drug with 14 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
7
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
1
trials recruiting
14
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Allo HSCT Using RIC and PTCy for Hematological Diseases
Allopurinol to Prevent Cirrhosis Related Morbidities
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
Clinical Trials (14)
Allo HSCT Using RIC and PTCy for Hematological Diseases
Allopurinol to Prevent Cirrhosis Related Morbidities
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
Lowering Uric Acid in Live Kidney Donors
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
RDEA3170 and Allopurinol Combination Study in Gout Subjects
Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin
Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence
Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability
All 14 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 14